Cephalon, Inc.

Cephalon, Inc.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Contact Details

Office Address

Cephalon, Inc.
41 Moores Road
Frazer, PA, USA 19355
Phone: (610) 344-0200
Fax: (610) 738-6590


Founder, Chairman, Chief Exec. Officer and Pres.

Dr. Frank Baldino Jr.

Chief Operating Officer

Mr. Kevin Buchi

Business Reviews for Cephalon, Inc.

Related Companies